A Prospective Evaluation of Two Rapid Phenotypical Antimicrobial Susceptibility Technologies for the Diagnostic Stewardship of Sepsis

Table 4

Antimicrobial susceptibility testing results of Pheno system compared to the routine SensiTitre system. The summary of discrepancies in percent is reported in brackets. Cefotaxime result was predicted according to ceftriaxone SIR classification (EUCAST rules v1.2.0.4).

(a)

Antimicrobial agent	Number of very major errors (%)	Number of major errors (%)	Number of minor errors (%)	AST agreement (%)	Total
Gram-positives
Ampicillin	0/2	1/2 (50.0)	0/4	3/4 (75.0)	4
Ceftaroline	0/0	0/3	0/3	3/3 (100.0)	3
Doxycycline	0/0	0/2	0/2	2/2 (100.0)	2
Erythromycin	0/1	0/2	0/3	3/3 (100.0)	3
Trimethoprim-sulfamethoxazole	0/0	0/3	0/3	3/3 (100.0)	3
Daptomycin	0/0	0/5	0/5	5/5 (100.0)	5
Linezolid	0/0	0/7	0/7	7/7 (100.0)	7
Vancomycin	0/1	1/6 (16.7)	0/7	6/7 (85.7)	7
Cefoxitin	0/0	0/2	0/2	2/2 (100.0)	2
MLS screening	0/0	0/2	0/2	2/2 (100.0)	2
Total	0/4	2/34 (5.9)	0/38	36/38 (94.7)	38

(b)

Antimicrobial agent	Number of very major errors (%)	Number of major errors (%)	Number of minor errors (%)	AST agreement (%)	Total
Gram-negatives
Ampicillin/sulbactam	0/27	3/7 (42.9)	0/34	31/34 (91.2)	34
Piperacillin/tazobactam	2/15 (13.3)	3/28 (10.7)	4/46 (8.7)	37/46 (80.4)	46
Cefazoline	0/1	0/0	0/1	1/1 (100.0)	1
Cefepime	0/13	1/30 (3.3)	6/46 (13.0)	39/46 (84.8)	46
Ceftazidime	0/15	1/28 (3.6)	2/45 (4.4)	42/45 (93.3)	45
Cefotaxime	0/0	0/1	0/1	1/1 (100.0)	1
Ertapenem	1/9 (11.1)	0/35	1/44 (2.3)	42/44 (95.5)	44
Meropenem	1/9 (11.1)	0/37	5/46 (10.9)	40/46 (87.0)	46
Gentamicin	0/7	3/38 (7.9)	1/45 (2.2)	41/45 (91.1)	45
Amikacin	0/9	0/33	5/46 (10.9)	41/46 (89.1)	46
Tobramycin	0/0	0/2	0/2	2/2 (100.0)	2
Ciprofloxacin	0/22	0/22	2/46 (4.4)	44/46 (95.7)	46
Colistin	0/5	2/38 (5.3)	0/43	41/43 (95.4)	43
Total	4/132 (3.0)	13/299 (4.4)	26/445 (5.8)	402/445 (90.3)	445